ストックスクリーナーアプリを入手
6.48
1.09%
0.07
前日終値:
$6.41
開ける：
$6.29
24時間の取引高:
11,132
Relative Volume:
0.30
時価総額：
$47.45M
収益：
$7.00M
当期純損益:
$-61.71M
株価収益率:
-0.7675
EPS:
-8.4433
ネットキャッシュフロー:
$-56.66M
1週間 パフォーマンス:
-4.85%
1か月 パフォーマンス:
-4.14%
6か月 パフォーマンス:
+72.80%
1年 パフォーマンス:
+14.89%
1日の値動き範囲:
$6.29
$6.6803
1週間の範囲:
$6.29
$6.79
52週間の値動き範囲:
$3.5334
$7.45
Kezar Life Sciences Inc Stock (KZR) Company Profile
名前
Kezar Life Sciences Inc
セクター
電話
650-822-5600
住所
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
6.48 | 46.94M | 7.00M | -61.71M | -56.66M | -8.4433 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-17 | ダウングレード | Jefferies | Buy → Hold |
| 2025-10-17 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-08-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2018-07-16 | 開始されました | Jefferies | Buy |
| 2018-07-16 | 開始されました | Wells Fargo | Outperform |
| 2018-07-16 | 開始されました | William Blair | Outperform |
すべてを表示
Kezar Life Sciences Inc (KZR) 最新ニュース
Kezar Life Sciences (KZR) to Release Earnings on Tuesday - Defense World
Highs Report: Can Kezar Life Sciences Inc maintain its current growth rate2026 Key Highlights & Weekly Breakout Watchlists - baoquankhu1.vn
If You Invested $1,000 in Kezar Life Sciences (KZR) - Stock Titan
Bull Bear: Is EEIQ still a buy after recent gains2026 Big Picture & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Analyst Downgrade: Is Kezar Life Sciences Inc undervalued by DCF analysis2026 Retail Activity & Daily Market Momentum Tracking - baoquankhu1.vn
Kezar Life Sciences Inc expected to post a loss of $1.23 a shareEarnings Preview - TradingView
Kezar Life Sciences, Inc.: Fundamental Analysis and Financial Ratings | 2KZ0 | US49372L2097 - marketscreener.com
Enodia jumps ahead in Sec61 targeting, adds Kezar’s program - BioWorld MedTech
Spring break for biotech deals? - BioCentury
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Deal Watch: Enodia Turns To Kezar To Advance Sec61 Programs - Citeline News & Insights
Enodia acquires Sec61 assets from Kezar Life Sciences - bioworld.com
Enodia acquires Kezar’s Sec61 program assets for $127M potential By Investing.com - Investing.com Canada
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences - PharmiWeb.com
Kezar Divests Sec61 Program to Refocus on Core Pipeline - TipRanks
Enodia Therapeutics strengthens Sec61 portfolio through acquisition of preclinical assets from Kezar Life Sciences - marketscreener.com
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition Of Preclinical Assets From Kezar Life Sciences - TradingView
Kezar Life Sciences Sells Sec61 Program to Enodia Therapeutics for Upfront Cash, Up to $127M Milestones - TradingView
Kezar Life Sciences (NASDAQ: KZR) sells Sec61 assets to Enodia with $127M milestones - Stock Titan
Kezar Life Sciences (KZR) Price Target Decreased by 52.00% to 6.12 - MSN
Entry Recap: Is Kezar Life Sciences Inc a play on infrastructure spendingBear Alert & Verified Chart Pattern Signals - baoquankhu1.vn
How cyclical is Kezar Life Sciences Inc. (2KZ0) stock compared to rivalsMarket Sentiment Summary & Reliable Price Breakout Signals - Naître et grandir
Layoff Watch: Why is Kezar Life Sciences Inc stock going upTake Profit & Safe Capital Growth Tips - baoquankhu1.vn
Downgrade Watch: What are Kezar Life Sciences Incs recent SEC filings showingTrade Exit Report & Community Trade Idea Sharing - baoquankhu1.vn
KZR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quarterly Trades: Will CRISPR Therapeutics AG benefit from government policyJuly 2025 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
Aug Analyst Calls: Why is Kezar Life Sciences Inc stock going upInsider Buying & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Activity Recap: Is Kezar Life Sciences Inc undervalued by DCF analysisTrade Risk Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Volume: Is Kezar Life Sciences Inc undervalued by DCF analysisBull Run & Weekly Return Optimization Plans - baoquankhu1.vn
Buy Signal: Will Stratus Properties Inc benefit from current market trendsPortfolio Performance Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
BML Capital Management LLC Has $2.81 Million Holdings in Kezar Life Sciences, Inc. $KZR - Defense World
Will Kezar Life Sciences Inc. stock recover faster than peersProduct Launch & Technical Confirmation Alerts - mfd.ru
Kezar Life Sciences (NASDAQ:KZR) Shares Up 0.3% – What’s Next? - Defense World
How Kezar Life Sciences Inc. stock reacts to Fed rate cuts2025 Short Interest & Daily Profit Maximizing Tips - mfd.ru
Will Kezar Life Sciences Inc. benefit from government policyJuly 2025 EndofMonth & Community Trade Idea Sharing - mfd.ru
Is Kezar Life Sciences Inc. trading at a discountTrade Exit Summary & Long Hold Capital Preservation Plans - mfd.ru
What are Kezar Life Sciences Inc.’s recent SEC filings showingJuly 2025 Fed Impact & Consistent Growth Equity Picks - mfd.ru
Is Kezar Life Sciences Inc. stock positioned for long term growthTrade Exit Summary & Entry Point Strategy Guides - mfd.ru
Published on: 2026-02-09 08:28:44 - baoquankhu1.vn
Chipmakers Recap: What is the next catalyst for Kezar Life Sciences IncJobs Report & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Average Rating of “Reduce” from Analysts - Defense World
Sectors Review: Will Kezar Life Sciences Inc benefit from government policy2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - baoquankhu1.vn
What is the next catalyst for Kezar Life Sciences Inc.July 2025 News Drivers & Community Consensus Stock Picks - bollywoodhelpline.com
ETF Watch: Will OXLCG benefit from geopolitical trendsJuly 2025 Patterns & Low Drawdown Trading Techniques - baoquankhu1.vn
Growth Review: Should I hold or sell Kezar Life Sciences Inc now2025 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
Layoff Tracker: SonomaBio Downsizes To Extend Runway - BioSpace
Sentiment Watch: Why Kezar Life Sciences Inc stock could rally in 2025Market Activity Summary & Free Technical Confirmation Trade Alerts - Bộ Nội Vụ
Published on: 2026-01-12 22:48:52 - ulpravda.ru
Kezar Life Sciences (KZR) to Discuss Zetomipzomib with FDA - GuruFocus
Kezar Life Sciences: FDA Division Grants Type C Meeting To Discuss Development Of Zetomipzomib - Nasdaq
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - The AI Journal
Kezar Life Sciences Inc (KZR) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):